Factors Affecting Morbidity and Mortality in Gastrectomy Cases with Splenectomy

Yıl 2022, Cilt: 5 Sayı: 2, 168 - 173, 01.05.2022

Tolga Kalaycı , Ümit Haluk İliklerden , Çetin Kotan

https://doi.org/10.19127/bshealthscience.972815

Öz

Gastric cancer is a worldwide health problem. The addition of splenectomy to gastrectomy is a controversial issue, especially
in cases located on the greater curvature. In this study, it is aimed to find the factors affecting morbidity and mortality in gastrectomy
cases with splenectomy. Patients who underwent surgery for gastric cancer in Van Yuzuncu Yil University, Department of General
Surgery between January 2010 and January 2018 were retrospectively selected. Splenectomy cases were filtered out in all gastrectomy
patients. Preoperative, intraoperative and postoperative data of the patients were collected. The effects of the collected parameters on
morbidity and mortality were evaluated. A p value of less than 0.05 was considered statistically significant. 45 patients were included
in the study. The mean age of all patients was 64.2 years (32-85) and the male to female ratio was 27/18. Thirty seven cases (82.2%)
were operated under elective conditions. The most common tumor location was cardia (n=24, 53.3%) and the most common surgical
method (n=39) was total gastrectomy (86.7%). Morbidity and mortality rate of the study were 46.6% (n=21) and 17.8% (n=8),
respectively. Mortality increased in patients who were operated in emergency conditions and received neoadjuvant therapy, p=0.002
and P=0.044, respectively. While surgery under emergency conditions increased mortality, preoperative neoadjuvant treatment
decreased mortality. However, there was no factor affecting morbidity. Splenectomy in gastric cancer surgery, if possible, should be
performed under elective conditions and after neoadjuvant therapy to reduce mortality

Anahtar Kelimeler

Emergency surgery, Gastrectomy, Morbidity, Mortality, Neoadjuvant therapy, Splenectomy.

Kaynakça

• Ajani JA, Bentrem DJ, Besh S, D’Amico TA, Das P, Denlinger C, Glasgow RE. 2013. Gastric cancer, version 2.2013. J Nat Comp Cancer Netw, 11(5): 531-546.
• Association JGC. 2017. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer, 20(1): 1-19.
• Chen XL, Yang K, Zhang WH, Chen XZ, Zhang B, Chen ZX, Hu JK. 2014. Metastasis, risk factors and prognostic significance of splenic hilar lymph nodes in gastric adenocarcinoma. Plos One, 9(6): e99650.
• Ciesielski M, Kruszewski WJ, Walczak J, Szajewski M, Szefel J, Wydra J, Czerepko M. 2017. Analysis of postoperative morbidity and mortality following surgery for gastric cancer. Surgeon volume as the most significant prognostic factor. Przeglad Gastroenterol, 12(3): 215.
• Coco D, Leanza S. 2019. Indications for surgery in non-traumatic spleen disease. Open Acc Macedonian J Med Sci, 7(17): 2958.
• Collaborators GRF. 2016. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388(10053): 1659.
• Correa P. 2013. Gastric cancer: overview. Gastroenterol Clin North America, 42(2): 211.
• Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. 2002. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery, 131(4): 401-407.
• Fujita T, Matai K, Kohno S, Itsubo K. 1996. Impact of splenectomy on circulating immunoglobulin levels and the development of postoperative infection following total gastrectomy for gastric cancer. J British Surg, 83(12): 1776-1778.
• Galizia G, Lieto E, De Vita F, Castellano P, Ferraraccio F, Zamboli A, De Stefano L. 2015. Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. Surgery, 157(2): 285-296.
• Hong ZL, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin M. 2017. A preoperative scoring system to predict the risk of No. 10 lymph node metastasis for advanced upper gastric cancer: a large case report based on a single-center study. Oncotarg, 8(45): 80050.
• Huang CM, Zhang JR, Zheng CH, Li P, Xie JW, Wang JB, Chen QY. 2014. A 346 case analysis for laparoscopic spleen-preserving no. 10 lymph node dissection for proximal gastric cancer: a single center study. Plos One, 9(9): e108480.
• Hyung WJ, Yang HK, Han SU, Lee YJ, Park JM, Kim JJ, Lee HJ. 2019. A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi-center phase II clinical trial, KLASS 03. Gastric Cancer, 22(1): 214-222.
• Ito H, Inoue H, Odaka N, Satodate H, Mukai S, Omoto T, Kudo SE. 2013. Prognostic impact of prophylactic splenectomy for upper-third gastric cancer: a cohort study. Anticancer Res, 33(1): 277-282.
• Jeong O, Jung MR, Ryu SY. 2019. Clinicopathological features and prognostic impact of splenic hilar lymph node metastasis in proximal gastric carcinoma. European J Surg Oncol, 45(3): 432-438.
• Jeong O, Kim HG, Ryu SY, Park YK, Jung MR. 2018. Adverse prognostic impact of splenectomy on survival in gastric carcinoma patients: Regression and propensity score matching analysis of 1074 patients. Plos One, 13(9): e0203820.
• Ji X, Fu T, Bu ZD, Zhang J, Wu XJ, Zong XL, Ji JF. 2016. Comparison of different methods of splenic hilar lymph node dissection for advanced upper-and/or middle-third gastric cancer. BMC Cancer, 16(1): 1-8.
• Jp, JGCA. 2011. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer, 14: 113-123.
• Li C, Kim S, Lai J, Oh S, Hyung W, Choi W, Noh S. 2009. Lymph node dissection around the splenic artery and hilum in advanced middle third gastric carcinoma. European J Surg Oncol, 35(7): 709-714.
• Nashimoto A, Yabusaki H, Matsuki A. 2012. The significance of splenectomy for advanced proximal gastric cancer. Int J Surg Oncol, 2012: 301530. DOI: 10.1155/2012/301530.
• Oh SJ, Hyung WJ, Li C, Song J, Kang W, Rha SY, Clinic YGC. 2009. The effect of spleen‐preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. J Surg Oncol, 99(5): 275-280.
• Ohkura Y, Haruta S, Shindoh J, Tanaka T, Ueno M, Udagawa H. 2017. Efficacy of prophylactic splenectomy for proximal advanced gastric cancer invading greater curvature. World J Surg Oncol, 15(1): 1-7.
• Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Mabilia A. 2014. Treatment of gastric cancer. World J Gastroenterol, 20(7): 1635.
• Purkayastha J, Yadav J, Talukdar A, Das G, Pegu N, Madhav S, Mamidala V. 2020. Radical gastrectomy: still the gold standard treatment for gastric cancer—our experience from a tertiary care center from northeast India. Indian J Surg Oncol, 11(1): 66-70.
• Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Imamura H. 2017. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Annals of Surg, 265(2): 277-283.
• Siegel RL, Miller KD. 2019. Jemal Ahmedin. Cancer statistics, 2019. Cancer J Clinicians, 69(1): 7-34.
• Son SY, Shin DJ, Park YS, Oo AM, Jung DH, Lee CM, Kim HH. 2017. Spleen-preserving lymphadenectomy versus splenectomy in laparoscopic total gastrectomy for advanced gastric cancer. Surg Oncol, 26(2): 207-211.
• Thrumurthy SG, Chaudry MA, Hochhauser D, Mughal M. 2013. The diagnosis and management of gastric cancer. BMJ, 347: f6367.
• Toge T, Kameda A, Kuroi K, Seto Y, Yamada H, Hattori T. 1985. The role of the spleen in immunosuppression and the effects of splenectomy on prognosis in gastric cancer patients. Nihon Geka Gakkai Zasshi, 86(9): 1120-1123.
• Tsuda S, Oleynikov D, Gould J, Azagury D, Sandler B, Hutter M, Satava R. 2015. SAGES TAVAC safety and effectiveness analysis: da Vinci® surgical system (Intuitive Surgical, Sunnyvale, CA). Surg Endosc, 29(10): 2873-2884.
• Usui S, Tashiro M, Haruki S, Arita K, Ito K, Matsumoto A, Takiguchi N. 2016. Spleen preservation versus splenectomy in laparoscopic total gastrectomy with D 2 lymphadenectomy for gastric cancer: A comparison of short‐term outcomes. Asian J Endosc Surg, 9(1): 5-13.
• Valenti V, Hernandez‐Lizoaín J, Beorlegui M, Diaz‐Gozalez J, Regueira F, Rodriguez J, Cienfuegos J. 2011. Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy. J Surg Oncol, 104(2): 124-129.
• Vasas P, Wiggins T, Chaudry A, Bryant C, Hughes FS. 2012. Emergency presentation of the gastric cancer; prognosis and implications for service planning. World J Emerg Surg, 7(1): 1-7.
• Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Unverzagt S. 2017. Chemotherapy for advanced gastric cancer. Cochrane Database Systematic Reviews, Issue 8, John Wiley & Sons, Ltd., New York, US, pp: 177.
• Wang W, Li Z, Tang J, Wang M, Wang B, Xu Z. 2013. Laparoscopic versus open total gastrectomy with D2 dissection for gastric cancer: a meta-analysis. J Cancer Res Clin Oncol, 139(10): 1721-1734.
• Watanabe M, Kinoshita T, Enomoto N, Shibasaki H, Nishida T. 2016. Clinical significance of splenic hilar dissection with splenectomy in advanced proximal gastric cancer: an analysis at a single institution in Japan. World J Surg, 40(5): 1165-1171.
• Wohnrath DR, Araujo RL. 2019. D2 lymphadenectomy for gastric cancer as an independent prognostic factor of 10-year overall survival. European J Surg Oncol, 45(3): 446-453.
• Zhang CH, Zhan WH, He YL, Chen CQ, Huang MJ, Cai SR. 2007. Spleen preservation in radical surgery for gastric cardia cancer. Annals Surg Oncol, 14(4): 1312-1319.
• Zhang H, Pang D, Xu H, Ren Y, Liu C. 2014. Is concomitant splenectomy beneficial for the long-term survival of patients with gastric cancer undergoing curative gastrectomy? A single-institution study. World J Surg Oncol, 12(1): 1-7.